57 related articles for article (PubMed ID: 23053662)
1. Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels.
Diorio C; Lemieux J; Provencher L; Hogue JC; Vachon E
Breast Cancer Res Treat; 2012 Nov; 136(2):573-9. PubMed ID: 23053662
[TBL] [Abstract][Full Text] [Related]
2. Obesity and Breast Cancer: Interaction or Interference with the Response to Therapy?
Riondino S; Formica V; Valenzi E; Morelli C; Flaminio V; Portarena I; Torino F; Roselli M
Curr Oncol; 2023 Jan; 30(1):1220-1231. PubMed ID: 36661743
[TBL] [Abstract][Full Text] [Related]
3. Obesity and Risk of Recurrence in Patients With Breast Cancer Treated With Aromatase Inhibitors.
Harborg S; Cronin-Fenton D; Jensen MR; Ahern TP; Ewertz M; Borgquist S
JAMA Netw Open; 2023 Oct; 6(10):e2337780. PubMed ID: 37831449
[TBL] [Abstract][Full Text] [Related]
4. Increased Clinical Pain Locations and Pain Sensitivity in Women After Breast Cancer Surgery: Influence of Aromatase Inhibitor Therapy.
Zhu Y; Loggia ML; Edwards RR; Flowers KM; Muñoz-Vergara DW; Partridge AH; Schreiber KL
Clin J Pain; 2022 Dec; 38(12):721-729. PubMed ID: 36136765
[TBL] [Abstract][Full Text] [Related]
5. Endothelial dysfunction in breast cancer survivors on aromatase inhibitors: changes over time.
Shaaban A; Petersen A; Beckwith H; Florea N; Potter DA; Yee D; Vogel RI; Duprez D; Blaes AH
Cardiooncology; 2024 May; 10(1):27. PubMed ID: 38693561
[TBL] [Abstract][Full Text] [Related]
6. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer.
Morris PG; Hudis CA; Giri D; Morrow M; Falcone DJ; Zhou XK; Du B; Brogi E; Crawford CB; Kopelovich L; Subbaramaiah K; Dannenberg AJ
Cancer Prev Res (Phila); 2011 Jul; 4(7):1021-9. PubMed ID: 21622727
[TBL] [Abstract][Full Text] [Related]
7. Endothelial Dysfunction in Breast Cancer Survivors on Aromatase Inhibitors: Changes over Time.
Shaaban A; Petersen A; Beckwith H; Florea N; Potter DA; Yee D; Vogel RI; Duprez D; Blaes AH
Res Sq; 2023 Apr; ():. PubMed ID: 37066265
[TBL] [Abstract][Full Text] [Related]
8. Incidence and Treatment Efficacy of Trigger Finger in the Breast Cancer Population on Aromatase Inhibitors.
Regent-Smith AJ; Childers EJ; Dzwierzynski WW; Morgan AL
Hand (N Y); 2023 Mar; 18(2):250-253. PubMed ID: 34078170
[TBL] [Abstract][Full Text] [Related]
9. Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation.
Johansson H; Guerrieri-Gonzaga A; Gandini S; Bertelsen BE; Macis D; Serrano D; Mellgren G; Lazzeroni M; Thomas PS; Crew KD; Kumar NB; Briata IM; Galimberti V; Viale G; Vornik LA; Aristarco V; Buttiron Webber T; Spinaci S; Brown PH; Heckman-Stoddard BM; Szabo E; Bonanni B; DeCensi A
NPJ Breast Cancer; 2024 Jan; 10(1):7. PubMed ID: 38238336
[TBL] [Abstract][Full Text] [Related]
10. Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer.
Pfeiler G; Königsberg R; Hadji P; Fitzal F; Maroske M; Dressel-Ban G; Zellinger J; Exner R; Seifert M; Singer C; Gnant M; Dubsky P
Br J Cancer; 2013 Sep; 109(6):1522-7. PubMed ID: 24002592
[TBL] [Abstract][Full Text] [Related]
11. Effects of aromatase inhibitors and body mass index on steroid hormone levels in women with early and advanced breast cancer.
Elliott KM; Dent J; Stanczyk FZ; Woodley L; Coombes RC; Purohit A; Palmieri C
Br J Surg; 2014 Jul; 101(8):939-48. PubMed ID: 24687409
[TBL] [Abstract][Full Text] [Related]
12. Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study.
El-Attar AA; Ibrahim OM; Alhassanin SA; Essa ES; Mostafa TM
Eur J Clin Pharmacol; 2023 Feb; 79(2):299-309. PubMed ID: 36562831
[TBL] [Abstract][Full Text] [Related]
13. The Importance of Breast Adipose Tissue in Breast Cancer.
Kothari C; Diorio C; Durocher F
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32796696
[TBL] [Abstract][Full Text] [Related]
14. Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population.
Liu YL; Saraf A; Catanese B; Lee SM; Zhang Y; Connolly EP; Kalinsky K
Breast Cancer Res Treat; 2018 Jan; 167(1):277-288. PubMed ID: 28948418
[TBL] [Abstract][Full Text] [Related]
15. Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole.
Sini V; Lunardi G; Cirillo M; Turazza M; Bighin C; Giraudi S; Levaggi A; Piccioli P; Bisagni G; Gnoni R; Stridi G; Porpiglia M; Picardo E; Ponzone R; Marenco D; Mansutti M; Puglisi F; Del Mastro L
Br J Cancer; 2014 Mar; 110(5):1133-8. PubMed ID: 24448359
[TBL] [Abstract][Full Text] [Related]
16. Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole.
Kyvernitakis I; Knöll D; Struck M; Hars O; Bauer T; Hadji P
J Cancer Res Clin Oncol; 2014 Jan; 140(1):159-66. PubMed ID: 24292402
[TBL] [Abstract][Full Text] [Related]
17. A polymorphism at the 3'-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma.
Liu L; Bai YX; Zhou JH; Sun XW; Sui H; Zhang WJ; Yuan HH; Xie R; Wei XL; Zhang TT; Huang P; Li YJ; Wang JX; Zhao S; Zhang QY
Int J Mol Sci; 2013 Sep; 14(9):18973-88. PubMed ID: 24065098
[TBL] [Abstract][Full Text] [Related]
18. Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved.
Lønning PE; Eikesdal HP
Endocr Relat Cancer; 2013 Aug; 20(4):R183-201. PubMed ID: 23625614
[TBL] [Abstract][Full Text] [Related]
19. Exposures to synthetic estrogens at different times during the life, and their effect on breast cancer risk.
Hilakivi-Clarke L; de Assis S; Warri A
J Mammary Gland Biol Neoplasia; 2013 Mar; 18(1):25-42. PubMed ID: 23392570
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
